GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Embecta Corp (FRA:JX7) » Definitions » Total Receivables

Embecta (FRA:JX7) Total Receivables : €211 Mil (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Embecta Total Receivables?

Embecta's Total Receivables for the quarter that ended in Dec. 2024 was €211 Mil.


Embecta Total Receivables Historical Data

The historical data trend for Embecta's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Embecta Total Receivables Chart

Embecta Annual Data
Trend Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Total Receivables
Get a 7-Day Free Trial 101.88 128.01 134.43 149.08 222.37

Embecta Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 189.27 153.64 226.12 222.37 210.58

Embecta Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables


Embecta Total Receivables Related Terms

Thank you for viewing the detailed overview of Embecta's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Embecta Business Description

Traded in Other Exchanges
Address
300 Kimball Drive, Suite 300, Parsippany, NJ, USA, 07054
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.

Embecta Headlines

No Headlines